918
Participants
Start Date
February 24, 2017
Primary Completion Date
October 26, 2017
Study Completion Date
October 26, 2017
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
0.5 milliliter (mL), Intramuscular
Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine
0.5 mL, Intramuscular
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
0.5 mL, Intramuscular
Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine
0.5 mL, Intramuscular
Investigator Site 404, Ludwigsfelde
Investigator Site 204, Galicia
Investigational Site 310, Turku
Investigator Site 406, Hamburg
Investigator Site 415, Hamburg
Investigator Site 205, Madrid
Investigator Site 202, Madrid
Investigational Site 303, Pori
Investigational Site 308, Tampere
Investigator Site 201, Seville
Investigator Site 413, Datteln
Investigator Site 408, Goch
Investigator Site 401, Bramsche
Investigational Site 305, Seinäjoki
Investigator Site 412, Aschaffenburg
Investigational Site 304, Kokkola
Investigator Site 411, Bönnigheim
Investigator Site 407, Bretten
Investigator Site 409, Rosenheim
Investigational Site 307, Oulu
Investigator Site 402, Tauberbischofsheim
Investigator Site 403, Tauberbischofsheim
Investigational Site 309, Espoo
Investigational Site 301, Helsinki
Investigational Site 306, Helsinki
Investigational Site 302, Järvenpää
Investigational Site 102, Budapest
Investigational Site 101, Budapest
Investigational Site 104, Győr
Investigational Site 105, Miskolc
Investigational Site 103, Szeged
Investigational Site 106, Székesfehérvár
Investigator Site 203, Barcelona
Sanofi Pasteur, a Sanofi Company
INDUSTRY